https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab591/6310839
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

Conclusions
In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease. IVM did not have an effect on AEs or severe AEs. IVM is not a viable option to treat COVID-19 patients.

イベルメクチン投与はプラセボと比較して、新型コロナウィルスによる死亡率も入院日数も減らさない